Gilead's BLA For CAR T Cell Therapy Gets FDA Acceptance

www.investing.com/analysis/gileads-bla-for-car-t-cell-therapy-gets-fda-acceptance-200506455

By Zacks Investment Research | Feb 10, 2020 09:12PM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

GILD

+1.87%

Add to/Remove from Watchlist

NVS

+0.46%

Add to/Remove from Watchlist

GSK

+0.88%

Add to/Remove from Watchlist

KNSA

+0.56%

Add to/Remove from Watchlist

Gilead Sciences, Inc. (NASDAQ:GILD) announced that the FDA accepted Kite’s Biologics License Application (BLA) and granted Priority Review designation to investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19.

The company is seeking approval of KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

The BLA is supported by data from the single-arm, open-label, phase II ZUMA-2 study, which showed that 93% of patients responded to a single infusion of KTE-X19, including 67% of patients achieving a complete response, as assessed by an Independent Radiologic Review Committee.

The FDA has set a target action date of Aug 10, 2020.

KTE-X19 is currently in phase I/II studies, being evaluated in acute lymphoblastic leukemia (ALL), MCL and chronic lymphocytic leukemia (CLL).

Meanwhile, the European Medicines Agency (EMA) recently validated the Marketing Authorization Application for KTE-X19 in the European Union. The candidate has been granted Breakthrough Therapy Designation (BTD) by the FDA and Priority Medicines (PRIME) designation by the EMA for relapsed or refractory MCL.

A potential approval will give Gilead a second cell therapy treatment in its portfolio.

Gilead’s Yescarta was the first CAR T cell therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

We note that the massive decline in sales of the HCV franchise has propelled Gilead to focus on the HIV franchise, Yescarta and other newer avenues. The rapid adoption of Biktarvy propels the HIV business amid stiff competition from the likes of GlaxoSmithKline (NYSE:GSK) .

Gilead’s stock has gained 5.5% in the past year against the industry's decline of 2.2%.

However, the uptake of Yescarta has not been per expectations, given the exorbitant cost and competition from Novartis’ (NYSE:NVS) Kymriah. Gilead has also collaborated with Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to conduct a phase II, multicenter study of mavrilimumab, which is an investigational, fully-human monoclonal antibody that targets granulocyte macrophage colony-stimulating factor receptor alpha, in combination with Yescarta in patients with relapsed or refractory large B-cell lymphoma. Gilead’s intention to foray into the inflammation market to diversify the revenue base is encouraging as well.

Gilead currently carries a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?

Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Kiniksa Pharmaceuticals, Ltd. (KNSA): Free Stock Analysis Report

Original post

E-Mini Final Day of Month By Al Brooks - Mar 31, 2023

Emini daily charto Today is the final day of the month. The bulls have a bull reversal bar, closing near their high. The bulls will want another bull trend day and paint as little...

Nasdaq 100 Hits 7-Month High With Room to Rally Further By Matthew Weller - Mar 31, 2023

The Nasdaq 100 is trading at a 7-month high, up more than 20% in three months to enter a new bull market The tech-heavy index recently saw a “golden cross” of the...

3 Stocks With Dividends Paid Out Every Month By Brett Owens - Mar 31, 2023

It doesn’t get any better than monthly dividends. Getting paid every 30 days aligns nicely with our monthly bill schedule. Today we’ll discuss three monthly dividend...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

5.00%

May 03, 2023

ECB

3.50%

May 04, 2023

BOE

4.25%

May 11, 2023

SNB

1.50%

Jun 22, 2023

RBA

3.60%

Apr 04, 2023

BOC

4.50%

Apr 12, 2023

RBNZ

4.75%

May 24, 2023

BOJ

-0.10%

Apr 28, 2023

CBR

7.50%

Apr 28, 2023

RBI

6.50%

Apr 03, 2023

PBOC

3.65%

BCB

13.75%

May 03, 2023

US 30	33,340.5	+481.5	+1.47%
US 500	4,110.6	+59.8	+1.48%
Dow Jones	33,274.15	+415.12	+1.26%
S&P 500	4,109.31	+58.48	+1.44%
Nasdaq	12,221.91	+208.44	+1.74%
S&P 500 VIX	18.70	0.00	0.00%
Dollar Index	102.285	+0.464	+0.46%

Crude Oil WTI	75.70	+1.33	+1.79%
Brent Oil	79.94	+1.34	+1.70%
Natural Gas	2.166	+0.062	+2.95%
Gold	1,986.70	-11.00	-0.55%
Silver	24.227	+0.238	+0.99%
Copper	4.0825	-0.0090	-0.22%
US Soybeans	1,505.00	+31.00	+2.10%

U.S. 10Y	3.473	-0.017	-0.48%
U.S. 30Y	3.651	-0.037	-1.01%
U.S. 5Y	3.5836	-0.0274	-0.76%
U.S. 3M	4.7733	-0.0287	-0.60%
US 10Y T-Note	114.92	+0.34	+0.30%
Euro Bund	136.20	+0.83	+0.61%
10-2 Yield Spread	-53.71	-2.44	4.76%

Apple	164.90	+2.54	+1.56%
Alphabet A	103.73	+2.84	+2.81%
Tesla	207.46	+12.18	+6.24%
Amazon.com	103.29	+1.29	+1.26%
Netflix	345.48	+7.05	+2.08%
Meta Platforms	211.94	+4.10	+1.97%
Bank of America	28.60	+0.30	+1.06%

Gilead's BLA For CAR T Cell Therapy Gets FDA Acceptance

Related Articles